• 1
    Zhang ZL, Chen W, Li YH, et al. Stage T1N0M0 renal cell carcinoma: the prognosis in Asian patients. Chin J Cancer. 2011; 30: 772-778.
  • 2
    Choong CV, Tang T, Chay WY, et al. Nasal metastases from renal cell carcinoma are associated with Memorial Sloan-Kettering Cancer Center poor-prognosis classification. Chin J Cancer. 2011; 30: 144-148.
  • 3
    Sanjmyatav J, Schubert J, Junker K. Comparative study of renal cell carcinoma by CGH, multicolor-FISH and conventional cytogenic banding analysis. Oncol Rep. 2005; 14: 1183-1187.
  • 4
    Zhang ZL, Li YH, Xiong YH, et al. Oncological outcome of surgical treatment in 336 patients with renal cell carcinoma. Chin J Cancer. 2010; 29: 995-999.
  • 5
    Cook KM, Figg WD. Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin. 2010; 60: 222-243.
  • 6
    Qian CN, Huang D, Wondergem B, Teh BT. Complexity of tumor vasculature in clear cell renal cell carcinoma. Cancer. 2009; 115(10 suppl): 2282-2289.
  • 7
    Yao X, Qian CN, Zhang ZF, et al. Two distinct types of blood vessels in clear cell renal cell carcinoma have contrasting prognostic implications. Clin Cancer Res. 2007; 13: 161-169.
  • 8
    Dunphy F, Stack BC Jr, Boyd JH, Dunleavy TL, Kim HJ, Dunphy CH. Microvessel density in advanced head and neck squamous cell carcinoma before and after chemotherapy. Anticancer Res. 2002; 22: 1755-1758.
  • 9
    Gadducci A, Viacava P, Cosio S, et al. Intratumoral microvessel density, response to chemotherapy and clinical outcome of patients with advanced ovarian carcinoma. Anticancer Res. 2003; 23( 1B): 549-556.
  • 10
    Sauer G, Deissler H. Angiogenesis: prognostic and therapeutic implications in gynecologic and breast malignancies. Curr Opin Obstet Gynecol. 2003; 15: 45-49.
  • 11
    Green FL, Page DL, Fleming ID, et al, eds. AJCC Cancer Staging Manual.6th ed. New York: Springer-Verlag; 2002.
  • 12
    Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982; 6: 655-663.
  • 13
    Qian CN, Berghuis B, Tsarfaty G, et al. Preparing the “soil”: the primary tumor induces vasculature reorganization in the sentinel lymph node before the arrival of metastatic cancer cells. Cancer Res. 2006; 66: 10365-10376.
  • 14
    Russ JC. The Image Processing Handbook.4th ed. Boca Raton, FL: CRC Press; 2002.
  • 15
    Ridler TW, Calvard S. Picture thresholding using an iterative selection method. IEEE Trans Syst Man Cybernetics. 1978; 8: 630-632.
  • 16
    Leibovich BC, Blute ML, Cheville JC, et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer. 2003; 97: 1663-1671.
  • 17
    Baluk P, Hashizume H, McDonald DM. Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev. 2005; 15: 102-111.
  • 18
    Armulik A, Abramsson A, Betsholtz C. Endothelial/pericyte interactions. Circ Res. 2005; 97: 512-523.
  • 19
    Huang D, Ding Y, Li Y, et al. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma. Cancer Res. 2010; 70: 1053-1062.
  • 20
    Kienast Y, von Baumgarten L, Fuhrmann M, et al. Real-time imaging reveals the single steps of brain metastasis formation. Nat Med. 2010; 16: 116-122.
  • 21
    Cooke VG, LeBleu VS, Keskin D, et al. Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. Cancer Cell. 2012; 21: 66-81.
  • 22
    Qin L, Bromberg-White JL, Qian CN. Opportunities and challenges in tumor angiogenesis research: back and forth between bench and bed. Adv Cancer Res. 2012; 113: 191-239.
  • 23
    Wahl O, Oswald M, Tretzel L, Herres E, Arend J, Efferth T. Inhibition of tumor angiogenesis by antibodies, synthetic small molecules and natural products. Curr Med Chem. 2011; 18: 3136-3155.